Gérard Hascoët, Chairman
Gérard is a serial entrepreneur in the medtech field. In the eighties he founded Technomed International, a company developing non-invasive therapeutic technologies dedicated to urology. He grew the company to its IPO with €50M sales and a significant profitability. In the 1990s he founded two companies: IMMI developing neurosurgery image-guided robotic systems and Sometec developing non-invasive hemodynamic monitoring dedicated to anesthesiology and intensive care. Both companies were acquired by US based companies respectively ISS and Arrow International. From 2008 to 2011 as CEO he turned around SpineVision a developer and manufacturer of spinal implants. In 2009 Gerard co-founded MD Start, a European incubator of medical device innovations.
Prior to becoming an entrepreneur, Gérard began his career in the French Thomson Group, where he held various management positions over 15 years in the medtech branch. Gérard is an engineer from E.C.E Paris.
Gérard is Executive Chairman of MD Start, Chairman of the Board of EOS Imagine, Director of the Board of Limflow, Director of the Board of SpineVision, Director of the Board of APD, and Director of the Board of Altamir. He is also Venture Partner for Sofinnova Partners.
Philippe Boucheron representing Bpifrance Participations
Between 1993 and 1996, Philippe Boucheron worked as an associate at BioCapital LP, one of the largest Canadian venture capital funds focusing on healthcare. From 1997 to 2000, he directed the mid-caps equity research team at ING Barings Ferri, Paris. Here, he spent a significant part of his time following French and European listed biotech companies. In 2000, he co-founded the Bioam Funds dedicated to early-stage life science investments and became Investment Manager, then in 2004 Managing Partner. After the merger of Bioam with CDC entreprises in July 2010, Philippe Boucheron joined the CDC Entreprises life sciences’ team as Investment Manager. In 2013, CDC Entreprises, FSI and Oséo merged to create Bpifrance. Since, he is deputy chief of the Life Investments BU and sits on Bpifrance Investissement’s Investment Committee. Philippe Boucheron also sits on the boards of Ademtech, Integragen, SSI, Advicenne, ART, GamaMabs and CorWave. Philippe Boucheron holds an engineering degree in Biochemical Engineering and Microbial genetics from the Institut National des Sciences Appliquées in Toulouse, a MSc in Biochemical Engineering from the Ecole Polytechnique of Montreal, and a MBA from INSEAD.
Emmanuelle Coutanceau from Novo Seeds
Emmanuelle joined Novo A/S in September 2015 as Investment Director of Novo Seeds. Emmanuelle obtained her MSc degree from the Agrocampus Ouest (France) in 2003 and her PhD degree in 2006 from the Paris 7 University, for her work on the immunosuppressive properties of a bacterial toxin, conducted at Pasteur Institute (Paris, France). Prior joining Novo Seeds, Emmanuelle was Investment Director at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. Emmanuelle has more than 8 years of experience in venture capital investment and was part of Omnes capital (formerly Crédit Agricole Private Equity) from 2007 until 2014. She was in charge of the Seed Stage Investment Program and actively invested in Belgium and The Netherlands. Emmanuelle serves on the Board of Directors of Avilex Pharma, Minervax and Pcovery.
Raúl Martín-Ruiz representing Ysios Capital
Raúl Martín-Ruiz is a Principal in Ysios Capital, a leading independent Spanish venture capital firm that provides private equity financing to human healthcare and life sciences companies. Prior to joining Ysios in 2008 he developed his career in Laboratorios Almirall, initially working in corporate business development (Licensing In and Licensing Out) and then as responsible for developing and managing the business of the company in the Americas and Africa through licensees and distributors. Initially he was trained as a researcher in the areas of Central Nervous System pharmacology in the Department of Pharmacology of the UPV-EHU (University of the Basque Country), and in neurochemistry in the Department of Neurochemistry of the IIBB-CSIC (Institute for Biomedical Research of Barcelona-Spanish National Research Council). Other than CorWave, he is a Member of the Board of Directors of STAT Diagnostica and Prexton Therapeutics. He has a B.Sc. in Biological Sciences by the UPV-EHU and holds a Ph.D. in Neurosciences by the same university and the CSIC.
Antoine Papiernik representing Sofinnova Partners
Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, Addex, Orexo, NovusPharma (then sold to CTI), Movetis (then sold to Shire) and Stentys, which went public respectively on the Zürich stock exchange, the Stockholm stock exchange, the Milan Nuovo Mercato, the Belgium Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis) and Ethical Oncology Science (EOS, sold to Clovis Oncology). He has also invested in and is a board member of private companies Auris Medical, MD Start, Mainstay, ReCor, Pixium Vision and Shockwave Medical. Antoine has an MBA from the Wharton School of Business, University of Pennsylvania.
In 2012 and 2011, Antoine was selected by Forbes for its “Midas List” of the world’s top venture capital investors. Antoine is one of the only Europeans on the list, and one of the few life science investors as well.
Michel Darnaud, independent board member
Mr. Darnaud is a seasoned executive with 30 years of industry experience in medical technology, including two decades in international senior management positions.
Since 2008 he has been president of the LivaNova’s Cardiopulmonary and Intercontinental business, with full global responsibility from R&D to sales. From 2005-2007, Mr. Darnaud was a consultant to executive search firm Spencer Stuart, where he established a presence for the firm in the medical technology sector in Europe. From 1998-2005, Mr. Darnaud was president of Boston Scientific’s European business, with full P/L responsibility across eight divisions, including interventional cardiology. Additionally, he was chairman of Eucomed (European Medical Device Industry Association) in 2004/2005. He currently serves as chairman of the Board of Stentys and Xeltis.